Trials / Completed
CompletedNCT02531932
Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer
A Multi-Centered Randomized Phase II Study Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Amy Tiersten · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of carboplatin compared to the combination of carboplatin and everolimus for the treatment of advanced triple-negative breast cancer (TNBC). Study close to accrual
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Carboplatin | Carboplatin will be administered if ANC \> 1.0 and platelets are \>75k |
| DRUG | Everolimus | The study drug Everolimus will be self-administered (by the patients themselves). |
Timeline
- Start date
- 2015-12-16
- Primary completion
- 2024-09-30
- Completion
- 2024-10-19
- First posted
- 2015-08-25
- Last updated
- 2025-02-19
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02531932. Inclusion in this directory is not an endorsement.